A Phase Ia/II, Multicenter Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Efficacy of JMT203 in Patients with Cancer Cachexia
Age ≥ 18 years old;
Voluntarily participate in the study and sign the informed consent form;
Age ≥ 18 years old;
Voluntarily participate in the study and sign the informed consent form;
Presence of reversible causes leading to decreased food intake;
Patients with dysphagia or poor food digestion and absorption, including gastrointestinal obstruction, active inflammatory bowel disease, or short bowel syndrome;
Patients with cachexia caused by clearly identified other causes, such as severe chronic obstructive pulmonary disease, uncontrolled thyroid disease, vital organ failure, or Acquired Immune Deficiency Syndrome （AIDS）;
Patients receiving tube feeding or parenteral nutrition therapy during the screening period;